CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is currently recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Lymphoma
2		Additional conditions recognized in this trial
			Lymphoma, Mantle-Cell
3		More general conditions related to this trial
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphatic Diseases
			Lymphoma, Non-Hodgkin
			Lymphoproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
4		Interventions listed in this trial
			rituximab
			temsirolimus
5		More general drug interventions related to this trial
			Antineoplastic Agents
			Antirheumatic Agents
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
6		Sponsors listed in this trial
			North Central Cancer Treatment Group
			National Cancer Institute (NCI)